Conflict of interest statement:
BAW receives research funding from Novartis. CFD is the Chief Adjudicator for the Stryker EVOLVE Flow Diverter clinical trial. KAS receives research funding from Novartis, Pfizer, Daiichi-Sankyo, Sanofi, and Dova. EM is a consultant for Novartis. IF is a consultant for NobelPharma, Novartis, and Apogee Pharmaceuticals and is the Chair of the Data Safety Monitoring Board for Pfizer. All authors declare no commercial or financial relationships that could be construed as a potential conflict of interest.